HF 808

1st Engrossment - 90th Legislature (2017 - 2018) Posted on 03/08/2017 12:40pm

A bill for an act
relating to human services; allowing the early periodic screening, diagnosis, and
treatment program to cover stiripentol; amending Minnesota Statutes 2016, section
256B.0625, subdivision 64.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2016, section 256B.0625, subdivision 64, is amended to
read:

Subd. 64.

Investigational drugs, biological products, and devices.

Medical assistance
and the early periodic screening, diagnosis, and treatment (EPSDT) program do not cover
costs incidental to, associated with, or resulting from the use of investigational drugs,
biological products, or devices as defined in section 151.375 deleted text begin . deleted text end new text begin , except that stiripentol may
be covered by the EPSDT program, only if all of the following conditions are met:
new text end

new text begin (1) the use of stiripentol is determined to be medically necessary;
new text end

new text begin (2) stiripentol is covered only for eligible enrollees with a documented diagnosis of
Dravet syndrome, regardless of whether an SCN1A genetic mutation is found, or children
with Malignant Migrating Partial Epilepsy in Infancy due to an SCN2A genetic mutation;
new text end

new text begin (3) all other available covered prescription medications that are medically necessary for
the patient have been tried without successful outcomes; and
new text end

new text begin (4) the United States Food and Drug Administration has approved the treating physician's
individual patient investigational new drug application (IND) for the use of stiripentol for
treatment.
new text end

new text begin This provision related to coverage of stiripentol does not apply to MinnesotaCare
coverage under chapter 256L.
new text end